143 related articles for article (PubMed ID: 17548110)
1. Non-small cell lung cancer cells produce a functional set of complement factor I and its soluble cofactors.
Okroj M; Hsu YF; Ajona D; Pio R; Blom AM
Mol Immunol; 2008 Jan; 45(1):169-79. PubMed ID: 17548110
[TBL] [Abstract][Full Text] [Related]
2. A mutation in factor I that is associated with atypical hemolytic uremic syndrome does not affect the function of factor I in complement regulation.
Nilsson SC; Karpman D; Vaziri-Sani F; Kristoffersson AC; Salomon R; Provot F; Fremeaux-Bacchi V; Trouw LA; Blom AM
Mol Immunol; 2007 Mar; 44(8):1835-44. PubMed ID: 17084897
[TBL] [Abstract][Full Text] [Related]
3. Mutations in complement factor I as found in atypical hemolytic uremic syndrome lead to either altered secretion or altered function of factor I.
Nilsson SC; Kalchishkova N; Trouw LA; Fremeaux-Bacchi V; Villoutreix BO; Blom AM
Eur J Immunol; 2010 Jan; 40(1):172-85. PubMed ID: 19877009
[TBL] [Abstract][Full Text] [Related]
4. Role of the C3b-binding site on C4b-binding protein in regulating classical pathway C5 convertase.
Rawal N; Pangburn MK
Mol Immunol; 2007 Feb; 44(6):1105-14. PubMed ID: 16979240
[TBL] [Abstract][Full Text] [Related]
5. Role of membrane cofactor protein (CD46) in regulation of C4b and C3b deposited on cells.
Barilla-LaBarca ML; Liszewski MK; Lambris JD; Hourcade D; Atkinson JP
J Immunol; 2002 Jun; 168(12):6298-304. PubMed ID: 12055245
[TBL] [Abstract][Full Text] [Related]
6. Genetic, molecular and functional analyses of complement factor I deficiency.
Nilsson SC; Trouw LA; Renault N; Miteva MA; Genel F; Zelazko M; Marquart H; Muller K; Sjöholm AG; Truedsson L; Villoutreix BO; Blom AM
Eur J Immunol; 2009 Jan; 39(1):310-23. PubMed ID: 19065647
[TBL] [Abstract][Full Text] [Related]
7. Functions of human complement inhibitor C4b-binding protein in relation to its structure.
Blom AM; Villoutreix BO; Dahlbäck B
Arch Immunol Ther Exp (Warsz); 2004; 52(2):83-95. PubMed ID: 15179322
[TBL] [Abstract][Full Text] [Related]
8. Phylogeny of C4b-C3b cleaving activity: similar fragmentation patterns of human C4b and C3b produced by lower animals.
Kaidoh T; Gigli I
J Immunol; 1987 Jul; 139(1):194-201. PubMed ID: 3295051
[TBL] [Abstract][Full Text] [Related]
9. Complement component C2, inhibiting a latent serine protease in the classical pathway of complement activation.
Halili MA; Ruiz-Gómez G; Le GT; Abbenante G; Fairlie DP
Biochemistry; 2009 Sep; 48(35):8466-72. PubMed ID: 19642650
[TBL] [Abstract][Full Text] [Related]
10. A cluster of positively charged amino acids in the alpha-chain of C4b-binding protein (C4BP) is pivotal for the regulation of the complement system and the interaction with bacteria.
Blom AM
Scand J Clin Lab Invest Suppl; 2000; 233():37-49. PubMed ID: 11317941
[TBL] [Abstract][Full Text] [Related]
11. The novel complement inhibitor human CUB and Sushi multiple domains 1 (CSMD1) protein promotes factor I-mediated degradation of C4b and C3b and inhibits the membrane attack complex assembly.
Escudero-Esparza A; Kalchishkova N; Kurbasic E; Jiang WG; Blom AM
FASEB J; 2013 Dec; 27(12):5083-93. PubMed ID: 23964079
[TBL] [Abstract][Full Text] [Related]
12. Mutations in alpha-chain of C4BP that selectively affect its factor I cofactor function.
Blom AM; Villoutreix BO; Dahlbäck B
J Biol Chem; 2003 Oct; 278(44):43437-42. PubMed ID: 12893820
[TBL] [Abstract][Full Text] [Related]
13. Complement inhibitor membrane cofactor protein (MCP; CD46) is constitutively shed from cancer cell membranes in vesicles and converted by a metalloproteinase to a functionally active soluble form.
Hakulinen J; Junnikkala S; Sorsa T; Meri S
Eur J Immunol; 2004 Sep; 34(9):2620-9. PubMed ID: 15307194
[TBL] [Abstract][Full Text] [Related]
14. Yersinia pestis Ail recruitment of C4b-binding protein leads to factor I-mediated inactivation of covalently and noncovalently bound C4b.
Ho DK; Skurnik M; Blom AM; Meri S
Eur J Immunol; 2014 Mar; 44(3):742-51. PubMed ID: 24765656
[TBL] [Abstract][Full Text] [Related]
15. Leptospira interrogans Lsa23 protein recruits plasminogen, factor H and C4BP from normal human serum and mediates C3b and C4b degradation.
Siqueira GH; Atzingen MV; de Souza GO; Vasconcellos SA; Nascimento ALTO
Microbiology (Reading); 2016 Feb; 162(2):295-308. PubMed ID: 26614523
[TBL] [Abstract][Full Text] [Related]
16. Membrane cofactor protein: importance of N- and O-glycosylation for complement regulatory function.
Liszewski MK; Leung MK; Atkinson JP
J Immunol; 1998 Oct; 161(7):3711-8. PubMed ID: 9759896
[TBL] [Abstract][Full Text] [Related]
17. Structural basis and functional effects of the interaction between complement inhibitor C4b-binding protein and DNA.
Okroj M; Jenkins HT; Herbert AP; Barlow PN; Blom AM
Mol Immunol; 2008 Nov; 46(1):62-9. PubMed ID: 18715646
[TBL] [Abstract][Full Text] [Related]
18. Analysis of binding sites on complement factor I that are required for its activity.
Nilsson SC; Nita I; Månsson L; Groeneveld TW; Trouw LA; Villoutreix BO; Blom AM
J Biol Chem; 2010 Feb; 285(9):6235-45. PubMed ID: 20044478
[TBL] [Abstract][Full Text] [Related]
19. Complement regulator C4BP binds to Staphylococcus aureus and decreases opsonization.
Hair PS; Wagner SM; Friederich PT; Drake RR; Nyalwidhe JO; Cunnion KM
Mol Immunol; 2012 Apr; 50(4):253-61. PubMed ID: 22333221
[TBL] [Abstract][Full Text] [Related]
20. Dysregulation of GIMAP genes in non-small cell lung cancer.
Shiao YM; Chang YH; Liu YM; Li JC; Su JS; Liu KJ; Liu YF; Lin MW; Tsai SF
Lung Cancer; 2008 Dec; 62(3):287-94. PubMed ID: 18462827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
